Current state of cardiovascular research in China

Scientific research drives discoveries and innovations that improve the prevention and management of cardiovascular disease. Cardiovascular research in China is thriving, as evidenced by the increasing number of publications and funding support for projects. However, data collection and the quality of publications require much improvement to propel the research field forward.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Zhou, M. et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (2019).

  2. 2.

    Nabel, E. G. & Braunwald, E. A tale of coronary artery disease and myocardial infarction. N. Engl. J. Med. 366, 54–63 (2012).

  3. 3.

    Ministry of Science and Technology of the People’s Republic of China. 2017 statistics on investment in research and development [Chinese]. Ministry of Science and Technology of the People’s Republic of China (2017).

  4. 4.

    Lansky, A. et al. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. Lancet 392, 1117–1126 (2018).

  5. 5.

    Han, Y. et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA 313, 1336–1346 (2015).

  6. 6.

    Huo, Y. et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA 313, 1325–1335 (2015).

  7. 7.

    Chen, S. L. et al. Double kissing crush versus provisional stenting for left main distal bifurcation lesions: DKCRUSH-V randomized trial. J. Am. Coll. Cardiol. 70, 2605–2617 (2017).

  8. 8.

    Hao, Y. et al. Sex differences in in-hospital management and outcomes of patients with acute coronary syndrome. Circulation 139, 1776–1785 (2019).

  9. 9.

    Li, J. et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet 385, 441–451 (2015).

  10. 10.

    Du, X. et al. Rationale and design of the Chinese Atrial Fibrillation Registry Study. BMC Cardiovasc. Disord. 16, 130 (2016).

Download references


The authors’ work is supported by the National Key Research and Development Program of China (2016YFC0900900 and 2016YFC0900902) and the Beijing Municipal Commission of Science and Technology (D171100006817001).

Author information

Correspondence to Changsheng Ma.

Ethics declarations

Competing interests

C.M. has received honoraria for presentations from AstraZeneca, Bayer Healthcare, Boehringer Ingelheim, Bristol-Myers Squibb, Johnson & Johnson and Pfizer. J.L. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liu, J., Ma, C. Current state of cardiovascular research in China. Nat Rev Cardiol 16, 575–576 (2019).

Download citation